Nanosonics (ASX: NAN): CORIS FDA Win Powers Medtech Story

Aditi Sarkar

29 July 2026 11:27 PM AEST

Nanosonics (ASX: NAN): CORIS FDA Win Powers Medtech Story

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

The trophon maker has landed CORIS's first US FDA 510(k) clearance and grown its installed base beyond 38,000 devices, but softer capital sales and a full-year 2027 launch temper the near-term story.
Nanosonics Limited (ASX: NAN) has moved back onto investor radars in 2026, helped by regulatory progress on its second product platform and steady growth in recurring revenue.
In the half-year to 31 December 2025, recurring revenue rose 9 per cent to A$75.7 million, spanning consumables, a 24 per cent lift in service and repairs, and ecosystem consumables.
The company reported an installed base of 38,080 devices globally at the end of the half, up 6 per cent, which it says protects roughly 29 million patients each year.

The trophon maker has landed CORIS's first US FDA 510(k) clearance and grown its installed base beyond 38,000 devices, but softer capital sales and a full-year 2027 launch temper the near-term story.

Company Overview

Nanosonics is a Sydney-based infection-prevention company built around trophon, an automated system that disinfects ultrasound probes between patients using its proprietary "sonically activated" hydrogen peroxide mist. The economics follow a classic razor-and-blade structure: hospitals and clinics buy the capital device (the "razor"), then generate recurring revenue through consumables, chemistry cartridges, service and repairs (the "blades").

Recent Developments

Nanosonics Limited (ASX: NAN) has moved back onto investor radars in 2026, helped by regulatory progress on its second product platform and steady growth in recurring revenue. On 10 June 2026 the shares traded about 4 per cent higher at A$3.44, according to market coverage from Kalkine, though that move came on light volume with no accompanying ASX announcement and should not be read as a response to fresh news.…

Financial and Operational Snapshot

Nanosonics remains debt-free and well capitalised. It closed FY2025 with about A$161 million in cash and generated free cash flow of roughly A$32 million, up 52 per cent. That balance sheet gives the company room to fund CORIS's commercialisation and continued research and development, historically running near the high-teens as a share of revenue, without external funding.

What May Be Watched Next

CORIS is Nanosonics' second platform, designed to automate the cleaning of flexible endoscopes, an area long dependent on manual brushing that carries well-documented infection risks. On 9 March 2026 the company announced CORIS had received its first US FDA 510(k) clearance, expanding the range of endoscopes the system is cleared to process. This followed an earlier De Novo clearance that established the regulatory pathway, with a second 510(k) submission in…

Key Risks

The near-term risks are real. Capital equipment sales have been softer, leaving recurring revenue to carry growth, and the reported EBIT gain of just 3 per cent shows how currency and rising operating expenses are compressing operating leverage. CORIS is still pre-scale, with meaningful revenue not expected until FY27 and execution risk across multi-jurisdiction launches and a pending second 510(k). The stock also trades on a demanding earnings multiple (a…

What does Nanosonics (ASX do?

What is the latest development?

What financial or operational point stands out?

What may be watched next?

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.